Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $589K | $2.04M | $2.43M | $1.19M | $71.0K | $0.00 | $0.00 | $4.01M | $1.04M | $7.70M |
| Revenue growth | — | 247.2% | 18.7% | -50.9% | -94.0% | -100.0% | — | — | -74.1% | 640.7% |
| Operating income | -$6.04M | -$9.13M | -$28.7M | -$53.8M | -$75.0M | -$108M | -$168M | -$223M | -$339M | -$517M |
| Operating margin | -1026.1% | -446.3% | -1182.5% | -4512.3% | -105567.6% | — | — | -5547.2% | -32613.5% | -6714.8% |
| Net income | -$6.02M | -$9.16M | -$27.1M | -$50.4M | -$73.8M | -$108M | -$164M | -$215M | -$298M | -$465M |
| Net margin | -1021.9% | -447.8% | -1116.8% | -4226.5% | -103960.6% | — | — | -5345.9% | -28720.7% | -6046.2% |
| EPS (diluted) | -$5.96 | -$6.68 | -$2.23 | -$2.09 | -$2.42 | -$2.80 | -$3.15 | -$3.69 | -$3.69 | -$4.95 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.47M | -$9.48M | -$19.5M | -$46.4M | -$62.0M | -$88.6M | -$115M | -$169M | -$230M | -$378M |
| Capital expenditures | $190K | $304K | $1.06M | $492K | $186K | $436K | $1.66M | $4.69M | $3.84M | $5.76M |
| Free cash flow | -$5.66M | -$9.78M | -$20.5M | -$46.9M | -$62.2M | -$89.0M | -$117M | -$173M | -$234M | -$384M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $12.2M | $14.2M | $45.0M | $40.3M | $93.1M | $201M | $32.7M | $54.9M | $265M | $102M |
| Total assets | — | $15.6M | $171M | $130M | $183M | $351M | $352M | $635M | $1.43B | $1.13B |
| Total liabilities | — | $920K | $11.2M | $13.2M | $14.5M | $19.1M | $35.8M | $96.2M | $110M | $134M |
| Shareholders' equity | -$6.20M | -$15.0M | $160M | $117M | $169M | $332M | $316M | $539M | $1.32B | $992M |
| Retained earnings | — | -$16.3M | -$43.4M | -$93.8M | -$168M | -$275M | -$439M | -$654M | -$952M | -$1.42B |
| Shares (wtd avg diluted) | — | 1.55M | 24.1B | 24.3M | 30.4M | 38.4M | 52.0M | 58.1M | 80.8M | 94.1M |
Every figure is extracted from Crinetics Pharmaceuticals, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.